CD274 and non-small cell lung carcinoma: Exosomal programmed death-ligand 1 (PD-L1), for example, has been shown in clinical settings to be a possible predictor of response to anti-PD-1 treatment in patients with non-small cell lung cancer (NSCLC) and melanoma [15].